Black Rock Inc. Spruce Biosciences, Inc. Transaction History

Black Rock Inc.

$4.23 Trillion
Q1 2024

A detailed history of Black Rock Inc. transactions in Spruce Biosciences, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 185,948 shares of SPRB stock, worth $137,601. This represents 0.0% of its overall portfolio holdings.

Number of Shares

185,948

Previous 261,016 28.76%

Holding current value

$137,601

Previous $764,000 80.89%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$0.7 - $5.49 $52,547 - $412,123	-75,068 Reduced 28.76%	185,948 $146,000
Q4 2023 Feb 13, 2024	BUY	$1.04 - $2.93 $2,615 - $7,368	2,515 Added 0.97%	261,016 $764,000
Q3 2023 Nov 13, 2023	SELL	$2.04 - $2.54 $5,055 - $6,294	-2,478 Reduced 0.95%	258,501 $584,000
Q2 2023 Aug 11, 2023	BUY	$1.92 - $2.6 $210,558 - $285,131	109,666 Added 72.48%	260,979 $561,000
Q1 2023 May 12, 2023	BUY	$1.15 - $3.17 $1,028 - $2,833	894 Added 0.59%	151,313 $334,000

Q4 2022 Feb 13, 2023	BUY	$0.99 - $1.19 $590 - $709	596 Added 0.4%	150,419 $165,000
Q3 2022 Nov 14, 2022	SELL	$1.37 - $2.19 $8,515 - $13,613	-6,216 Reduced 3.98%	149,823 $205,000
Q2 2022 Aug 12, 2022	SELL	$1.28 - $2.23 $478,099 - $832,938	-373,515 Reduced 70.53%	156,039 $272,000
Q1 2022 May 12, 2022	BUY	$1.85 - $4.59 $202,068 - $501,347	109,226 Added 25.99%	529,554 $1.06 Million
Q4 2021 Feb 10, 2022	SELL	$2.33 - $5.74 $2,164 - $5,332	-929 Reduced 0.22%	420,328 $1.88 Million
Q3 2021 Nov 09, 2021	BUY	$6.01 - $11.26 $8,822 - $16,529	1,468 Added 0.35%	421,257 $2.53 Million
Q2 2021 Aug 11, 2021	BUY	$10.12 - $17.46 $4.25 Million - $7.33 Million	419,789 New	419,789 $4.71 Million

Others Institutions Holding SPRB

# of Institutions

Shares Held

18.3M

Call Options Held

49K

Put Options Held

48.1K

View Full List

About SPRUCE BIOSCIENCES, INC.

Ticker SPRB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 23,560,200
Market Cap $17.4M
Description
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which i...

More about SPRB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account